Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | -0.38% | -.--% | +11.81% |
Apr. 03 | Kinnate Biopharma Inc. Announces Board Resignations | CI |
Apr. 03 | Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index | CI |
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 112M |
---|---|---|---|---|---|
Net income 2022 | -116M | Net income 2023 | -113M | EV / Sales 2022 | - |
Net cash position 2022 | 262M | Net cash position 2023 | 161M | EV / Sales 2023 | - |
P/E ratio 2022 |
-2.31
x | P/E ratio 2023 |
-0.98
x | Employees | 27 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.86% |
1 day | -0.38% | ||
3 months | +2.32% | ||
6 months | +17.78% | ||
Current year | +11.81% |
Managers | Title | Age | Since |
---|---|---|---|
Quah Cheng
CTO | Chief Tech/Sci/R&D Officer | - | - |
Richard Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-05-31 |
Priyanka Shah
IRC | Investor Relations Contact | - | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - | |
0.00% | 2 M€ | -.--% | ||
0.00% | 9 M€ | +9.22% | - |
1st Jan change | Capi. | |
---|---|---|
+11.81% | 125M | |
+46.44% | 54.63B | |
-6.90% | 39.92B | |
+37.07% | 38.82B | |
+13.34% | 26.86B | |
-11.17% | 26.22B | |
-21.73% | 18.78B | |
+25.86% | 12.21B | |
+0.72% | 12.16B | |
+25.80% | 11.94B |
- Stock Market
- Equities
- KNTE Stock